Clinical Trials Logo
  1. Home
  2. Adverse Events
  3. NCT01291667

Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinE — HOPES  

Adverse Events Clinical Trial

Official title:
A Phase III Randomized Study for HER2-Overexpressed Metastatic Breast Cancer Patients Treated by Trastuzumab( Cipterbin®) Plus vinorelbinE Simultaneously or Sequencely

Clinical Trial Summary

Breast cancer is the most common malignant disease and the most frequent causes of cancer mortality in females worldwide. The situation is same as the world in China. Trastuzumab has been proved valuable treatment for HER2-positive breast cancer patients. Cipterbin® is developing by Shanghai CP Guojian Pharmaceutical Co.Ltd.Now we carried on the phase III trial in order to prove Cipterbin® 's efficacy and safety.

Clinical Trial Description

n/a

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01291667
Study type Observational
Source Shanghai CP Guojian Pharmaceutical Co.,Ltd.
Contact
Status Completed
Phase Phase 3
Start date May 2009
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05390125 - Effectiveness of a Proficiency-based Progression Communication Training Programme
Completed NCT04012320 - Efficacy and Safety on the Use of Bisphosphonates in Paediatrics
Completed NCT02268331 - Comparison of Active vs. Passive Surveillance to Collect Adverse Events N/A
Completed NCT00244673 - Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination Phase 4
Recruiting NCT05038527 - ABM/P-15 Bone Graft vs Traditional Bone Graft in Adult Spinal Deformity Surgery N/A
Completed NCT00681395 - Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium Phase 1
Completed NCT05359666 - Retrospective Independent Safety Review of Closed Irrisept Study N/A
Recruiting NCT05311566 - PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer Phase 2
Recruiting NCT05311579 - Niraparib Plus Anlotinib for Recurrent Ovarian Cancer Phase 2
Recruiting NCT05310344 - Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer Phase 2
Completed NCT05815615 - Plasmapheresis: a Multi-modal Approach N/A
Completed NCT02130570 - Relative Patient Benefits of a Hospital-PCMH Collaboration Within an ACO to Improve Care Transitions N/A
Recruiting NCT05804188 - CRICKET: Critical Events in Anaesthetised Kids Undergoing Tracheal Intubation
Not yet recruiting NCT06117176 - Prospective Assessment Project of AirwaY Management-related Incidents in Adult Anaesthesia Care PAPAYA III
Recruiting NCT02725073 - Photodynamic Therapy in Locally Advanced Hilar Cholangiocarcinoma Phase 2
Completed NCT02928705 - Quality of Telemedically Guided Prehospital Analgesia N/A
Terminated NCT02011607 - Incidence of Adverse Airway Events in High Risk Patients Undergoing Upper GI Endoscopy Under Anesthesia
Withdrawn NCT01128127 - Strategies for Improving Proton Pump Inhibitors (PPIs) Prescription Associated to Non-steroidal Anti-inflammatory Drugs (NSAIDs) N/A
Completed NCT02310815 - ReSure Sealant Post Approval Study N/A
Recruiting NCT05709392 - Preterm DElayed Cord Clamping and Early Skin-to-Skin Contact: PreDECESS N/A